Biodexa Pharmaceuticals
BDRX
1 hedge funds and large institutions have $58.9K invested in Biodexa Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
29% more capital invested
Capital invested by funds: $45.8K → $58.9K (+$13.1K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
67% less funds holding
Funds holding: 3 → 1 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$18.2K |
| 2 |
Millennium Management
New York
|
-$14K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.89K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$2.6K |
| 5 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$865 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $57.2K | +$62K | +9 | New |
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $1.08K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $354 | -$6.89K | -1 | Closed |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $254 | – | – | – |
|
5
Morgan Stanley
New York
| $80 | – | – | – |
|
|
CSS
6
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$18.2K | -3 | Closed |
|
|
7
Millennium Management
New York
| – | -$14K | -2 | Closed |
|
|
BBA
8
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$865 | – | – |
|
|
FDCDDQ
9
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$12 | – | – |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$2.6K | – | – |
|
BDRX Hedge Fund Activity: Q3 2023 in Review
1 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q3 2023, worth a combined $58.9K — up 29% from $45.8K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BDRX and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $62K. The largest seller was Cubist Systematic Strategies, exiting entirely with an estimated $18.2K sold.
- 1 institutional investor held Biodexa Pharmaceuticals (BDRX) as of Q3 2023, down from 3 in Q2 2023.
- Funds reported $58.9K of Biodexa Pharmaceuticals stock for Q3 2023, up 29% quarter-over-quarter.
- 1 fund opened new Biodexa Pharmaceuticals positions in Q3 2023 and 3 closed out, a net change of -2 holders.
- The largest Biodexa Pharmaceuticals buyer in Q3 2023 was Susquehanna International Group, an estimated $62K added.
- The largest Biodexa Pharmaceuticals seller in Q3 2023 was Cubist Systematic Strategies, an estimated $18.2K sold.
Based on aggregated 13F filings for Q3 2023.